On 29 October, India’s controller general of patents, designs and trademarks, Chaitanya Prasad, rejected an application for a compulsory licence for a blood cancer drug, dasatinib, which was patented in India in 2006 by Bristol-Myers Squibb (BMS).
You must be a
subscribersubscribersubscribersubscriber
to read this content, please
subscribesubscribesubscribesubscribe
today.
For group subscribers, please click here to access.
Interested in group subscription? Please contact us.
你需要登录去解锁本文内容。欢迎注册账号。如果想阅读月刊所有文章，欢迎成为我们的订阅会员成为我们的订阅会员。
